Astragalus (Huang Qi)

Traditional Chinese immunomodulatory root with emerging evidence in chemotherapy-combined protocols

Key Points

• Astragalus polysaccharides (APS) and cycloastragenol activate NK cells, macrophages, and T-lymphocytes, enhancing innate and adaptive anti-tumor immunity.
• Several Chinese RCTs show improved survival and reduced chemotherapy toxicity when astragalus-based herbal formulas are combined with platinum chemotherapy for NSCLC.
• Cycloastragenol (a saponin in astragalus) activates telomerase, which may have anti-aging but theoretically pro-proliferative implications — requires monitoring.
• Most evidence derives from trials conducted in China with variable methodology; replication in Western trials is limited.
• Interacts with cyclophosphamide — may reduce its immunosuppressive effects (used therapeutically in some protocols but may undermine lymphoablative conditioning).
• Used as a core herb in many Traditional Chinese Medicine cancer support formulas (e.g., Zheng Qi Fu Zheng).

Traditional Use and Active Compounds

Astragalus membranaceus (Huang Qi, milk vetch) is one of the 50 fundamental herbs in Traditional Chinese Medicine (TCM), used for over 2,000 years as a Qi-tonifying and Wei-strengthening (defensive energy) herb. It occupies a central role in cancer support formulas within the TCM system, where cancer is conceptualized as arising from deficiency of Wei Qi (defensive vital force) combined with stagnation of Blood and Phlegm. The pharmacologically active constituents are three major classes: 1. **Astragalus polysaccharides (APS):** High-molecular-weight heteropolysaccharides that activate…

Clinical Evidence

The clinical evidence base for astragalus in oncology is almost entirely derived from Chinese clinical trials, with important methodological limitations including lack of placebo controls, inadequate randomization reporting, and publication bias toward positive results. **NSCLC Combined with Chemotherapy:** A 2006 meta-analysis by McCulloch et al. (J Clin Oncol) of 34 randomized trials involving 2,815 NSCLC patients found that astragalus-based Chinese herbal medicine combined with chemotherapy was associated with significantly improved 1-year survival (RR 1.33), improved tumor response, and…